Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714980 | 0.92 | TDP1 (0.42) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL7009795 | 0.91 | TDP1 (0.41) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL30680417 | 0.89 | ALDH1A1 (0.42) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL9219919 | 0.88 | HTT (0.51) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL9745314 | 0.85 | HTT (0.58) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL9186659 | 0.85 | GAA (0.56) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL30071516 | 0.85 | GAA (0.47) | GAACYP1A2CYP2C19MAPTLMNA | |
| SCHEMBL670736 | 0.85 | GAA (0.47) | GAACYP1A2CYP2C19MAPTLMNA | |
| SCHEMBL7162469 | 0.85 | MEN1 (0.41) | GAACYP1A2CYP2C19HPGDMAPT | |
| SCHEMBL1301604 | 0.84 | LMNA (0.43) | GAACYP1A2CYP2C19HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | claimed |
| JP-6048990-A | — | — | None | — | — | JP | disclosed |
| US-7879878-B2 | such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| CN-100471842-C | Carbostyril derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-03-25 | — | — | CN | disclosed |
| US-7488739-B2 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-02-10 | — | — | US | disclosed |
| CN-1826321-A | Quinolone derivative or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2006-08-30 | — | — | CN | disclosed |
| US-20060148806-A1 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1650192-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-0303291-B1 | Fluorinated benzoyl compounds | ASAHI GLASS CO LTD (JP) | 1995-04-26 | — | — | EP | disclosed |
| US-5380860-A | Preparation of beta-ketoesters useful in preparing quinolone antibiotics | PFIZER INC. (US) | 1995-01-10 | — | — | US | disclosed |
| JP-H0648990-A | PREPARATION OF BETA-KETOESTERS USEFUL IN PREPARING QUNOLONE ANTIBIOTICS | PFIZER INC | 1994-02-22 | — | — | JP | disclosed |
| EP-0527154-A1 | PROCESS FOR PREPARING 3,4-DIFLUOROANILINE | Pfizer Hospital Products Group, Inc. (US) | 1993-02-17 | — | — | EP | disclosed |
| US-5093515-A | Intermediate for quinolone carboxylic acid bactericide | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| US-5068449-A | FLUORINATED BENZOYL COMPOUNDS | ASAHI GLASS COMPANY, LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| WO-1991017138-A1 | PROCESS FOR PREPARING 3,4-DIFLUOROANILINE | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0449445-A2 | Preparation of beta-ketoesters useful in preparing quinolone antibiotics | PFIZER INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-4994610-A | Process for preparing fluorinated benzoyl compounds | ASAHI GLASS COMPANY, LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | THPO, ABL1, GMPS | GAA 1758/4885CYP1A2 2490/4885CYP2C19 200/4885 |
| US-20060148806-A1 | Quinolone derivative or salt thereof | THPO, ABL1, GMPS | GAA 1758/4885CYP1A2 2490/4885CYP2C19 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.